Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years
Background: Venetoclax is the first representative of a new class of targeted therapy, that inhibits selectively B-cell lymphoma-2 (BCL-2), an anti-apoptotic protein, frequently overexpressed in hematological malignancies. Venetoclax was approved by the Food and Drug Administration for chronic lymph...
Gardado en:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2025-07-01
|
| Series: | Therapeutic Advances in Hematology |
| Acceso en liña: | https://doi.org/10.1177/20406207251343116 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|